Positive initial data from a pivotal phase II expansion cohort evaluating investigational linvoseltamab (BCMAXCD3, formerly REGN5458) at the 200 mg dose recommended for further development in patients with heavily pre-treated, relapsed/refractory multiple myeloma, were presented at the 64th American Society of Hematology Annual Meeting and Exposition.
The EU has approved Sarclisa (isatuximab-irfc) in combination with a standard-of-care regimen, bortezomib, lenalidomide, and dexamethasone, for the treatment of adult patients with newly diagnosed multiple myeloma ineligible for autologous stem cell transplant, based on data from the IMROZ phase III study.
